Aptose Biosciences (APTO) said Tuesday the Nasdaq Hearings Panel has decided to delist its shares from the stock exchange on Wednesday due to the company's failure to comply with the equity requirement for continued listing.
The company said it was unable to regain compliance by March 31.
Aptose said it will review "all available options, including an appeal to the determination" and will apply to list on a US national securities exchange "at the appropriate time."
The company's shares were falling more than 51% in recent trading.
Price: 1.54, Change: -1.63, Percent Change: -51.41
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.